HERON THERAPEUTICS, INC. /DE/ Costs and Expenses
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Costs and Expenses of $28.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for the quarter ending 2026-06-30 was $28.14M, a 2.91% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for the quarter ending 2026-03-31 was $28.84M, a 5.66% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for the quarter ending 2025-12-31 was $29.43M, a 11.57% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for the quarter ending 2025-09-30 was $30.39M, a 9.28% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for fiscal 2025 was $116.09M, a 0.91% decline from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for fiscal 2024 was $117.17M, a 32.10% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for fiscal 2023 was $172.55M, a 24.14% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ costs and expenses for fiscal 2022 was $227.46M, a 25.22% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.14M 10-Q · filed 2026-08-10 | $56.98M 10-Q · filed 2026-08-10 | $86.41M derived: sum of 3 quarters · filed 2026-08-10 | $116.80M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $28.84M 10-Q · filed 2026-05-11 | $58.27M derived: sum of 2 quarters · filed 2026-05-11 | $88.66M derived: sum of 3 quarters · filed 2026-05-11 | $117.64M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $29.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.82M derived: sum of 2 quarters · filed 2026-02-26 | $88.80M derived: sum of 3 quarters · filed 2026-08-10 | $116.09M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $30.39M 10-Q · filed 2025-11-04 | $59.37M derived: sum of 2 quarters · filed 2026-08-10 | $86.66M 10-Q · filed 2025-11-04 | $113.04M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $28.98M 10-Q · filed 2026-08-10 | $56.27M 10-Q · filed 2026-08-10 | $82.65M derived: sum of 3 quarters · filed 2026-08-10 | $110.46M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $27.29M 10-Q · filed 2026-05-11 | $53.67M derived: sum of 2 quarters · filed 2026-05-11 | $81.48M derived: sum of 3 quarters · filed 2026-05-11 | $113.43M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $26.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $54.19M derived: sum of 2 quarters · filed 2026-02-26 | $86.14M derived: sum of 3 quarters · filed 2026-02-26 | $117.17M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $27.81M 10-Q · filed 2025-11-04 | $59.76M derived: sum of 2 quarters · filed 2025-11-04 | $90.78M 10-Q · filed 2025-11-04 | $125.35M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $31.95M 10-Q · filed 2025-08-08 | $62.98M 10-Q · filed 2025-08-08 | $97.54M derived: sum of 3 quarters · filed 2026-02-26 | $135.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $31.02M 10-Q · filed 2025-05-06 | $65.59M derived: sum of 2 quarters · filed 2026-02-26 | $103.75M derived: sum of 3 quarters · filed 2026-02-26 | $157.75M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $34.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $72.72M derived: sum of 2 quarters · filed 2026-02-26 | $126.73M derived: sum of 3 quarters · filed 2026-02-26 | $172.55M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $38.16M 10-Q · filed 2024-11-12 | $92.16M derived: sum of 2 quarters · filed 2024-11-12 | $137.99M 10-Q · filed 2024-11-12 | $175.74M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $54.01M 10-Q · filed 2024-08-06 | $74.17M 10-Q · filed 2023-08-14 | $99.83M 10-Q · filed 2024-08-06 | $136.84M 10-Q · filed 2023-08-14 | $137.59M derived: sum of 3 quarters · filed 2025-02-27 | $191.31M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $45.82M 10-Q · filed 2024-05-07 | $62.68M 10-Q · filed 2023-05-11 | $83.58M derived: sum of 2 quarters · filed 2025-02-27 | $137.30M derived: sum of 3 quarters · filed 2025-02-27 | $214.43M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $37.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $91.48M derived: sum of 2 quarters · filed 2025-02-27 | $168.61M derived: sum of 3 quarters · filed 2025-02-27 | $227.46M 10-K · filed 2025-02-27 | $282.33M 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $53.72M 10-Q · filed 2023-11-14 | $68.44M 10-Q · filed 2022-11-08 | $130.85M derived: sum of 2 quarters · filed 2023-11-14 | $189.70M 10-Q · filed 2023-11-14 | $231.95M 10-Q · filed 2022-11-08 | $291.42M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $77.13M 10-Q · filed 2023-08-14 | $163.51M 10-Q · filed 2023-08-14 | $237.70M derived: sum of 3 quarters · filed 2023-08-14 | $312.64M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $86.38M 10-Q · filed 2023-05-11 | $160.57M derived: sum of 2 quarters · filed 2023-05-11 | $235.51M derived: sum of 3 quarters · filed 2023-05-11 | $318.42M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $74.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $149.13M derived: sum of 2 quarters · filed 2023-03-29 | $232.04M derived: sum of 3 quarters · filed 2023-03-29 | $304.17M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $74.94M 10-Q · filed 2022-11-08 | $157.85M derived: sum of 2 quarters · filed 2022-11-08 | $229.98M 10-Q · filed 2022-11-08 | $311.88M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $82.91M 10-Q · filed 2022-08-09 | $155.04M 10-Q · filed 2022-08-09 | $236.94M derived: sum of 3 quarters · filed 2022-08-09 | $315.29M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $72.13M 10-Q · filed 2022-05-09 | $154.03M derived: sum of 2 quarters · filed 2022-05-09 | $232.38M derived: sum of 3 quarters · filed 2022-05-09 | $310.80M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $81.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $160.25M derived: sum of 2 quarters · filed 2022-02-28 | $238.67M derived: sum of 3 quarters · filed 2022-02-28 | $316.80M 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | $78.35M 10-Q · filed 2021-11-03 | $156.77M derived: sum of 2 quarters · filed 2021-11-03 | $234.90M 10-Q · filed 2021-11-03 | $329.35M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $78.42M 10-Q · filed 2021-08-09 | $156.55M 10-Q · filed 2021-08-09 | $251.00M derived: sum of 3 quarters · filed 2022-02-28 | $328.47M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $78.13M 10-Q · filed 2021-05-10 | $172.58M derived: sum of 2 quarters · filed 2022-02-28 | $250.06M derived: sum of 3 quarters · filed 2022-02-28 | $338.49M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $94.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $171.92M derived: sum of 2 quarters · filed 2022-02-28 | $260.36M derived: sum of 3 quarters · filed 2022-02-28 | $356.66M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $77.48M 10-Q · filed 2020-11-05 | $165.91M derived: sum of 2 quarters · filed 2020-11-05 | $262.22M 10-Q · filed 2020-11-05 | $342.38M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $88.44M 10-Q · filed 2020-08-05 | $184.74M 10-Q · filed 2020-08-05 | $264.90M derived: sum of 3 quarters · filed 2021-02-24 | $326.46M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $96.30M 10-Q · filed 2020-05-06 | $176.46M derived: sum of 2 quarters · filed 2021-02-24 | $238.03M derived: sum of 3 quarters · filed 2021-02-24 | $294.16M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $80.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $141.72M derived: sum of 2 quarters · filed 2021-02-24 | $197.85M derived: sum of 3 quarters · filed 2021-02-24 | $261.41M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $61.57M 10-Q · filed 2019-11-12 | $117.70M derived: sum of 2 quarters · filed 2019-11-12 | $181.25M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $56.13M 10-Q · filed 2019-08-05 | $119.69M 10-Q · filed 2019-08-05 | ||||||
| 2017-12-31 | $225.32M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |